Guadix Juan A, Zugaza José L, Gálvez-Martín Patricia
Departamento de Biología Animal, Facultad de Ciencias, Universidad de Málaga, Instituto Malagueño de Biomedicina (IBIMA), Málaga, España; BIONAND, Centro Andaluz de Nanomedicina y Biotecnología (Junta de Andalucía, Universidad de Málaga), Málaga, España.
Departamento de Genética, Antropología Física y Fisiología Animal, Facultad de Ciencia y Tecnología, Universidad del País Vasco-Euskal Herriko Unibertsitatea, Leioa, España; Achucarro Basque Center for Neuroscience Zamudio, España; IKERBASQUE, Fundación Vasca para la Ciencia, Bilbao, España.
Med Clin (Barc). 2017 May 10;148(9):408-414. doi: 10.1016/j.medcli.2016.11.033. Epub 2017 Jan 23.
Recent advances in the field of cell therapy and regenerative medicine describe mesenchymal stem cells (MSCs) as potential biological products due to their ability to self-renew and differentiate. MSCs are multipotent adult cells with immunomodulatory and regenerative properties, and, given their therapeutic potential, they are being widely studied in order to evaluate their viability, safety and efficacy. In this review, we describe the main characteristics and cellular sources of MSCs, in addition to providing an overview of their properties and current clinical applications, as well offering updated information on the regulatory aspects that define them as somatic cell therapy products. Cell therapy based on MSCs is offered nowadays as a pharmacological alternative, although there are still challenges to be addressed in this regard.
细胞治疗和再生医学领域的最新进展表明,间充质干细胞(MSCs)因其自我更新和分化能力而被视为潜在的生物制品。MSCs是具有免疫调节和再生特性的多能成体细胞,鉴于其治疗潜力,人们正在对其进行广泛研究,以评估其可行性、安全性和有效性。在本综述中,我们描述了MSCs的主要特征和细胞来源,概述了其特性和当前的临床应用,并提供了有关将其定义为体细胞治疗产品的监管方面的最新信息。如今,基于MSCs的细胞治疗作为一种药理学替代方法被提供,尽管在这方面仍有挑战需要解决。